Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Mk-1439
2. Pifeltro
1. 1338225-97-0
2. Mk-1439
3. Pifeltro
4. 3-chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile
5. 3-chloro-5-[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile
6. Mk1439
7. Doravirine (mk-1439)
8. Mk-1439a
9. 913p6lk81m
10. 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile
11. Benzonitrile, 3-chloro-5-((1-((4,5-dihydro-4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl)-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl)oxy)-
12. Doravirine [usan]
13. Doravirine [usan:inn]
14. Unii-913p6lk81m
15. 4ncg
16. Pifeltro (tn)
17. 2kw
18. Mk 1439
19. Doravirine [mi]
20. Doravirine [inn]
21. Doravirine [jan]
22. Doravirine; Mk-1439
23. Mk-1439(doravirine)
24. Doravirine [who-dd]
25. C17h11clf3n5o3
26. Doravirine (jan/usan/inn)
27. Schembl2509885
28. Chembl2364608
29. Doravirine [orange Book]
30. Dtxsid30158386
31. Amy16781
32. Bcp02296
33. Ex-a1968
34. Bdbm50508293
35. Delstrigo Component Doravirine
36. Mfcd22417167
37. S6492
38. Zinc72317283
39. Akos030528603
40. Cs-5924
41. Db12301
42. Sb17104
43. Doravirine Component Of Delstrigo
44. Ncgc00508866-01
45. Ac-33637
46. Hy-16767
47. Db-091410
48. D10624
49. F53303
50. A856128
51. Q6885419
52. S900006160
53. 3-chloro-5-[[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-3-pyridyl]oxy]benzonitrile
Molecular Weight | 425.7 g/mol |
---|---|
Molecular Formula | C17H11ClF3N5O3 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | 425.0502514 g/mol |
Monoisotopic Mass | 425.0502514 g/mol |
Topological Polar Surface Area | 98 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 860 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Doravirine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history. It is also indicated to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.
FDA Label
Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class.
In a clinical phase 2 trial evaluating a dose range of 0.25-2x the recommended dose of doravirine (in combination with emtricitabine/tenofovir) in HIV-1 infected subjects with no antiretroviral treatment history, no exposure-response relationship for efficacy was identified for doravirine. Furthermore, at a dose of 1200 mg, which provides approximately 4 times the peak concentration observed following the recommended dose, doravirine does not prolong the QT interval to any clinically relevant extent.
J05AG06
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AG - Non-nucleoside reverse transcriptase inhibitors
J05AG06 - Doravirine
Absorption
The absolute bioavailability of doravirine is 64% with a Tmax of 2 hours. Following oral [14C]doravirine administration, all of the administered dose was recovered and the agent is considered to be well absorbed. Moreover, its co-administration with food did not greatly alter doravirine's pharmacokinetic profile during clinical studies.
Route of Elimination
The primary route of elimination for doravirine is via cytochrome P450 3A4/5 metabolism. Only 6% of an administered dose is recovered in the urine unchanged, with even less unchanged drug found in the feces.
Volume of Distribution
The steady-state volume of distribution of doravirine following intravenous administration is 60.5 L.
Clearance
The oral and renal clearances of doravirine are 106 ml/min and 9.3 ml/min, respectively.
Following absorption, unchanged parent drug is the major circulating component in plasma. Its M9 metabolite - a product of cytochrome P450 3A4/5 mediated oxidative metabolism - is the most abundant doravirine metabolite in the circulation.
The elimination half-life determined of doravirine is 15 hours.
Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV-1. Reverse transcriptase is the enzyme with which HIV generates complementary DNA (cDNA) to its RNA genome - this cDNA is then inserted into the host cell genome, where it can be transcribed into viral RNA for the purposes of replication. Doravirine inhibits HIV-1 replication by non-competitively inhibiting HIV-1 reverse transcriptase. Doravirine does not, however, inhibit the human cellular DNA polymerases , , and mitochondrial DNA polymerase .
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-08-09
Pay. Date : 2022-06-17
DMF Number : 37216
Submission : 2022-06-23
Status : Active
Type : II
NDC Package Code : 68554-0132
Start Marketing Date : 2018-08-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38795
Submission : 2023-10-06
Status : Active
Type : II
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Doravirine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Doravirine, including repackagers and relabelers. The FDA regulates Doravirine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Doravirine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Doravirine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Doravirine supplier is an individual or a company that provides Doravirine active pharmaceutical ingredient (API) or Doravirine finished formulations upon request. The Doravirine suppliers may include Doravirine API manufacturers, exporters, distributors and traders.
click here to find a list of Doravirine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Doravirine DMF (Drug Master File) is a document detailing the whole manufacturing process of Doravirine active pharmaceutical ingredient (API) in detail. Different forms of Doravirine DMFs exist exist since differing nations have different regulations, such as Doravirine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Doravirine DMF submitted to regulatory agencies in the US is known as a USDMF. Doravirine USDMF includes data on Doravirine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Doravirine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Doravirine suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Doravirine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Doravirine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Doravirine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Doravirine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Doravirine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Doravirine suppliers with NDC on PharmaCompass.
Doravirine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Doravirine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Doravirine GMP manufacturer or Doravirine GMP API supplier for your needs.
A Doravirine CoA (Certificate of Analysis) is a formal document that attests to Doravirine's compliance with Doravirine specifications and serves as a tool for batch-level quality control.
Doravirine CoA mostly includes findings from lab analyses of a specific batch. For each Doravirine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Doravirine may be tested according to a variety of international standards, such as European Pharmacopoeia (Doravirine EP), Doravirine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Doravirine USP).
LOOKING FOR A SUPPLIER?